Bromobenzene detoxification in the human liver-derived HepG2 cell line

References

• Aden D. P., Fogel A., Plotkin S., Damjanov I., Knowles B. B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615–616
   PubMed Web of Science ®Google Scholar
• Anfosso F., Chomiki N., Alessi M. C., Vague P., Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line HepG2: metformin inhibits the stimulating effect of insulin. Journal of Clinical Investigation 1993; 91: 2185–2193
   PubMed Web of Science ®Google Scholar
• Berger M. L., Bhatt H., Combes B., Estabrook R. W. CC14-induced toxicity in isolated hepatocytes: the importance of direct solvent injury. Hepatology 1986; 6: 36–45
   PubMed Web of Science ®Google Scholar
• Bernheim F., Bernheim M. L. C., Wilburn K. M. The reaction between thiobarbituric acid and the oxidation products of certain lipids. Journal of Biological Chemistry 1948; 174: 257–264
   PubMed Web of Science ®Google Scholar
• Bhatt T. S., Coombs M., Di Giovanni J., Diamond L. Mutagenesis in chinese hamster cells by cyclopenta(a)phenanthrenes activated by a human hepatoma cell line. Cancer Research 1983; 43: 984–986
   PubMed Web of Science ®Google Scholar
• Bouma M. E., Rogier E., Verthier N., LaBarre C., Feldmann G. Further cellular investigation of the human hepatoblastoma-derived cell line, HepG2. Morphology and immunocytochemical studies of hepatic-secreted proteins. In Vitro Cellular Developmental Biology 1989; 25: 267–275
   PubMed Web of Science ®Google Scholar
• Brown M. W., Maldonado A. L., Meredith C. G., Speeg K. V. Effect of ketoconazole on hepatic oxidative drug metabolism. Clinical and Pharmacological Therapeutics 1985; 37: 290–297
   PubMed Web of Science ®Google Scholar
• Campart G. B., Canonera R., Mereto E., Ferro V. Cytotoxic and genotoxic effects of 10 N-nitroso compounds in a human hepatoma cell line (HepG2): comparison with human hepatocyte primary culture. Alternatives to Laboratory Animals 1989; 17: 22–27
   Google Scholar
• Casini A. G. M., Hyland R. J., Serroni A., Gilfor D., Farber J. L. Mechanisms of cell injury in the killing of cultured hepatocytes by bromobenzene. Journal of Biological Chemistry 1982; 257: 6721–6728
   PubMed Web of Science ®Google Scholar
• Comporti M. Three models of free-radical-induced cell injury. Chemico-Biological Interactions 1989; 72: 1–56
   PubMed Web of Science ®Google Scholar
• Conover C. A., Leake P. D. K. Insulin regulation of insulin-like growth factor-binding protein production in cultured HepG2 cells. Journal of Clinical and Endocrinological Metabolism 1990; 70: 1062–1067
   PubMed Web of Science ®Google Scholar
• Cresteil T., Jaiswal A. K., Eisen H. J. Transcriptional control of human cytochrome P450 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human tissue culture cell lines. Archives of Biochemical Biophysics 1987; 253: 233–240
   PubMed Web of Science ®Google Scholar
• Dansette P. M., Dubois G. C., Jerina D. M. Continuous fluorimetric assay of epoxide hydrase activity. Annals of Biochemistry 1978; 97: 340–345
   Google Scholar
• Dawson J. R., Adams D. J., Wolf C. R. Induction of drug metabolism in the human hepatoma cell line HepG2. Biochemical and Biophysical Research Communications 1985; 143: 52–57
   Google Scholar
• Dearfield K. L., Jacobson-Kram D., Buenaventura S. K., Williams J. R. In vitro assays of in vivo exposure to cyclophosphamide: induction of sister chromatic exchanges in peripheral lymphocytes, bone marrow cells and in cultured cells exposed to plasma. Mutation Research 1983; 158: 97–104
   Google Scholar
• Decad G. M., Hsieh D. P. H., Byard J. L. Maintenance of cytochrome P-450 and metabolism of aflatoxin B1 in primary hepatocyte cultures. Biochemical and Biophysical Research Communications 1977; 78: 279–287
   PubMed Web of Science ®Google Scholar
• Diamond L., Cherian K., Harvey R. G., Di Giovanni J. Mutagenic activity of methyl- and fluoro-substituted derivatives of polycyclic aromatic hydrocarbons in a human hepatoma (HepG2) cell-mediated assay. Mutation Research 1985; 136: 65–72
   Google Scholar
• Diamond L., Kruszewski F., Aden D. P., Knowles B. B., Baird W. M. Metabolic activation of benzo(a)pyrene by a human hepatoma cell line. Carcinogenesis 1980; 1: 871–875
   PubMed Web of Science ®Google Scholar
• Dierickx P. J. Cytotoxicity testing of 114 compounds by the determination of the protein content in HepG2 cell cultures. Toxicology in Vitro 1989; 3: 189–193
   PubMedGoogle Scholar
• Doostdar H., Duthie S. J., Burke M. D., Melvin W. T., Grant M. H. The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived HepG2 cells line. FEBS Letters 1988; 241: 15–18
   PubMed Web of Science ®Google Scholar
• Doostdar H., Demoz A., Burke M. D., Melvin W. T., Grant M. H. Variation in drug metabolizing enzyme activities during the growth of human HepG2 hepatoma cells. Xenobiotica 1990; 20: 435–441
   PubMed Web of Science ®Google Scholar
• Doostdar H., Burke M. D., Melvin W. T., Grant M. H. The effects of dimethyl-sulphoxide and 5-aminolaevulinic acid on the activities of cytochrome P450-dependent mixed function oxidase and UDP-glucuronosyl transferase activities in human HepG2 hepatoma cells. Biochemical Pharmacology 1991; 42: 1307–1313
   PubMedGoogle Scholar
• Doostdar H., Grant M. H., Melvin W. T., Wolf C., Burke M. D. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HepG2 hepatoma cells. Biochemical Pharmacology 1993; 46: 629–635
   PubMed Web of Science ®Google Scholar
• Duthie S. J., Coleman C. S., Grant M. H. Status of reduced glutathione in the human hepatoma cell line HepG2. Biochemical Pharmacology 1988; 37: 3365–3368
   PubMedGoogle Scholar
• Duthie S. J., Grant M. H. The toxicity of menadione and mitoxantrone in human liver-derived HepG2 hepatoma cells. Biochemical Pharmacology 1989a; 38: 1247–1255
   PubMedGoogle Scholar
• Duthie S. J., Grant M. H. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver-derived HepG2 hepatoma cells. British Journal of Cancer 1989b; 60: 566–571
   PubMed Web of Science ®Google Scholar
• Duthie S. J., Grant M. H. Comparative toxicity of bromobenzene in human adult hepatocytes, rat hepatocytes and human HepG2 hepatoma cells. Medical Science Research 1992; 20: 379–380
   Google Scholar
• Eling T., Boyd J., Reed G., Mason R., Sivarajah K. Xenobiotic metabolism by prostaglandin endoperoxide synthetase. Drug Metabolism Reviews 1983; 14: 1023–1053
   PubMed Web of Science ®Google Scholar
• Erickson S. K., Fielding P. E. Parameters of cholesterol metabolism in the human hepatoma cell line HepG2. Journal of Lipid Research 1986; 27: 875–883
   PubMedGoogle Scholar
• Fuki I. V., Preobrazhensky S. N., Misharin A. Y., Bushmakina N. G., Menschikov G. B., Repin V. S., Karpov R. S. Effects of cell cholesterol content on apolipoprotein B secretion and LDL receptor activity in the human hepatoma cell line HepG2. Biochimica et Biophysica Acta 1989; 1001: 235–238
   PubMed Web of Science ®Google Scholar
• Fukuda Y., Ishida N., Noguchi T., Kappas A., Sassa S. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochemical and Biophysical Research Communications 1992; 184: 960–965
   PubMed Web of Science ®Google Scholar
• Galbraith R. A. Heme binding to HepG2 human hepatoma cells. Journal of Hepatology 1990; 10: 305–310
   Google Scholar
• Galbraith R. A., Sassa S., Kappas A. Induction of haem synthesis in HepG2 human hepatoma cells by dimethylsulfoxide: a transcriptionally activated event. Biochemical Journal 1986; 237: 597–600
   PubMed Web of Science ®Google Scholar
• Grant M. H., Burke M. D., Hawksworth G. M., Duthie S. J., Engeset J., Petrie J. C. Human adult hepatocytes in primary monolayer culture: maintenance of mixed function oxidase and conjugation pathways of drug metabolism. Biochemical Pharmacology 1987; 36: 2311–2316
   PubMed Web of Science ®Google Scholar
• Grant M. H., Duthie S. J., Gray A. G., Burke M. D. Mixed-function-oxidase and UDP-glucuronyl-transferase activities in the human HepG2 hepatoma cell line. Biochemical Pharmacology 1988a; 37: 4111–4116
   PubMed Web of Science ®Google Scholar
• Grant M. H., Doostdar H., Maley M., Melvin W. T., Engeset J., Burke M. D. Glucuronidation in rat and human hepatocyte cultures and in human HepG2 hepatoma cells. Cellular and Molecular Aspects of Glucuronidation, G. Siest, J. Magdalu, B. Birchall, 1988b; 129–136, (Colloque INSERM/John Libbey Eurotext), 173
   Google Scholar
• Guarner F., Fremont-Smith M., Prieto J. Cytoprotective effect of prostaglandins on isolated river cells. Liver 1985; 5: 35–39
   PubMedGoogle Scholar
• Guenthner T. M. Selective inhibition and selective induction of multiple microsomal epoxide hydrolases. Biochemical Pharmacology 1986; 35: 839–845
   PubMed Web of Science ®Google Scholar
• Guillouzo A., Beaune P., Gascoin M. N., Campion J., Guengerich F. P., Guillouzo C. G. Maintenance of cytochrome P450 in cultured adult human hepatocytes. Biochemical Journal 1985; 34: 2991–2995
   Google Scholar
• Guzelian P. S., Bissell D. M. Effect of cobalt on synthesis of heme and cytochrome P-450 in the liver: studies of adult rat hepatocytes in primary monolayer culture and in vivo. Journal of Biological Chemistry 1976; 251: 4421–4427
   PubMed Web of Science ®Google Scholar
• Hall T. J., Cambridge G., James P. R. Development of a coculture system with induced HepG2 cells and K562 cells for examining drug metabolism in vitro. Studies with cyclophosphamide, andansetron and cisplatin. Research Communications and Chemical and Pathological Pharmacology 1991; 72: 161–168
   Google Scholar
• Hall T. G., James P. R., Cambridge G. Development of an in vitro hepatotoxicity assay for assessing the effect of chronic drug exposure. Research Communications and Chemical and Pathological Pharmacology 1993; 72: 249–256
   Google Scholar
• Havekes L., Van Hinsbergh V., Kempen H. J., Emeis J. The metabolism in vitro of human low-density lipoprotein by the human hepatoma cell line HepG2. Biochemical Journal 1983; 214: 951–958
   Google Scholar
• Havinga J. R., Lohse P., Beisiegel U. Immunoblotting and ligand blotting of the low density lipoprotein receptor of human liver, HepG2 cells and HeLa cells. FEBS Letters 1987; 216: 275–280
   Google Scholar
• Hsu I. C., Tokiwa T., Bennet W., Metcalf R. A., Welsh J. A., Sun T., Harris C. C. P53 mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993; 14: 987–992
   PubMed Web of Science ®Google Scholar
• Jollow D. J., Mitchell J. R., Zampaglione N., Gillette J. R. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatic metabolite. Pharmacology 1974; 11: 151–169
   PubMed Web of Science ®Google Scholar
• Knowles B. B., Howe C. C., Aden D. P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1990; 209: 497–499
   Google Scholar
• Labruzzo P., Yu X. F., Dufresne M. J. Induction of arylhydrocarbon hydroxylase and demonstration of a specific nuclear receptor for 2,3,7,8-tetrachloro-dibenzo-p-dioxin in two human hepatoma cell lines. Biochemical Pharmacology 1989; 38: 2339–2348
   PubMed Web of Science ®Google Scholar
• Liebman K. C. Effects of metyrapone on liver microsomal drug oxidations. Molecular Pharmacology 1969; 5: 1–9
   PubMedGoogle Scholar
• Limbosch S. Benzo(a)pyrene and aldrin metabolising activities in cultured human and rat hepatoma cell lines. Journal of the National Cancer Institute 1983; 71: 281–286
   PubMed Web of Science ®Google Scholar
• Locke S. J., Brauer M. The response of the rat liver in situ to bromobenzene—in vivo proton magnetic resonance imaging and P31 magnetic resonance spectroscopy studies. Toxicology and Applied Pharmacology 1991; 110: 436–428
   Google Scholar
• Long R. M., Moore L. Evaluation of the calcium mobilizing action of acetaminophen and bromobenzene in rat hepatocyte cultures. Journal of Biochemistry and Toxicology 1988; 3: 353–362
   PubMedGoogle Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–270
   PubMed Web of Science ®Google Scholar
• Maellara E., Casim A. F., Del Bello B., Comporti M. Lipid peroxidation and antioxidant systems in the liver injury produced by glutathione depleting agents. Biochemical Pharmacology 1990; 39: 1513–1521
   Google Scholar
• Marnett L. J., Wlodawer P., Samuelsson B. Cooxidation of organic substrates by the prostaglandin synthetase of sheep vesicular gland. Journal of Biological Chemistry 1975; 250: 8510–8517
   PubMed Web of Science ®Google Scholar
• Maurice M., Pritchard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal 1992; 6: 752–758
   PubMed Web of Science ®Google Scholar
• Mennes W. C., Van Holstein C. W. M., Noordhoek J., Blaauboer B. J. Comparative cytotoxicity of bromobenzene in primary cultures of rat and hamster hepatocytes and its relation to biotransformation. Toxicology in Vitro 1991; 5: 63–70
   Google Scholar
• Miller G. L. Protein determinations for large numbers of samples. Annals of Chemistry 1959; 31: 964–969
   Web of Science ®Google Scholar
• Morrison H., Hammarskjold V., Jernstrom B. Status of reduced glutathione in primary cultures of rat hepatocytes and the effect of conjugation of benzo(a)pyrene-7,8-dihydrodiol-9,10-oxide. Chemico-Biological Interactions 1983; 45: 235–242
   PubMed Web of Science ®Google Scholar
• Nelson K. F., Acosta D., Bruckner J. V. Long-term maintenance and induction of cytochrome P-450 in primary cultures of rat hepatocytes. Biochemical Pharmacology 1982; 31: 2211–2214
   PubMed Web of Science ®Google Scholar
• Nicotera P., Hartzell P., Boldi C., Svensson S., Bellomo G., Orrenius S. Cystamine induces toxicity in hepatocytes through the elevation of cytosolic Ca2+ and the stimulation of a nonlysosomal proteolytic system. Journal of Biological Chemistry 1986; 261: 14628–14635
   PubMed Web of Science ®Google Scholar
• Owens I. S., Nebert D. W. Aryl hydrocarbon hydroxylase induction in mammalian liver-derived cell cultures: stimulation of cytochrome P1450-associated enzyme activity by many inducing compounds. Molecular Pharmacology 1975; 11: 94–104
   PubMedGoogle Scholar
• Paine A. J., Hockin L. J. Nutrient imbalance causes the loss of cytochrome P-450 in liver cell culture: formulation of culture media which maintain cytochrome P-450 at in vivo concentrations. Biochemical Pharmacology 1980; 29: 3215–3218
   PubMed Web of Science ®Google Scholar
• Powell D., Lee P. D., DePaolis L. A., Morris S. L., Suwanichkul A. Dexamethasone stimulates expression of insulin-like growth factor binding protein-1 in HepG2 human hepatoma cells. Growth Regulation 1993; 3: 11–13
   Google Scholar
• Reid W. D., Krishna G. Centrolobular hepatic necrosis relating to covalent binding of metabolites of halogenated aromatic hydrocarbons. Experimental and Molecular Pathology 1973; 18: 80–99
   PubMed Web of Science ®Google Scholar
• Roberts E. A., Johnson K. C., Harper P. A., Okey A. B. Characterisation of the Ah receptor mediating arylhydrocarbon hydroxylase induction in the human liver cell line HepG2. Archives in Biochemistry and Biophysics 1990; 276: 442–450
   PubMed Web of Science ®Google Scholar
• Sassa S., Sugita O., Galbraith R. A., Kappas A. Drug metabolism by the human hepatoma cell HepG2. Biochemical and Biophysical Research Communications 1987; 143: 52–57
   PubMed Web of Science ®Google Scholar
• Saville B. A scheme for the colorimetic determination of microgram amounts of thiols. Analyst 1958; 83: 670–672
   Web of Science ®Google Scholar
• Shaw P. M., Barnes T. S., Cameron D., Engeset J., Melvin W. T., Omar G., Petrie J. C., Rush W. R., Snyder C. P., Whiting P. W., Wolf C. R., Burke M. D. Purification and characterisation of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochemical Journal 1989; 263: 653–663
   PubMed Web of Science ®Google Scholar
• Sormunen R., Eskelinen S., Lehto V. P. Bile canaliculus formation in cultured HepG2 cells. Laboratory Investigations 1993; 68: 652–662
   PubMed Web of Science ®Google Scholar
• Stein O., Haratz D., Schwartz R., Berry E. M., Stein Y. Modification of cellular fatty acid composition of HepG2 cells: effect of antioxidants on cholesterol esterification and secretion. Biochimica et Biophysica Acta 1989; 1003: 115–120
   Google Scholar
• Strom S. C., Jirtle R. L., Jones R. S., Novicki D. L., Rosenberg M. R., Novotny A., Irons G., McLain J. R., Michalopoulos G. Isolation, culture and transplantation of human hepatocytes. Journal of the National Cancer Institute 1982; 68: 771–775
   PubMed Web of Science ®Google Scholar
• Thor H., Moldeus P., Hermanson R., Hogberg J., Reed D. J., Orrenius S. Metabolic activation and hepatotoxicity: toxicity of bromobenzene in hepatocytes isolated from phenobarbital and diethylmaleate-treated rats. Archives of Biochemistry and Biophysics 1978; 188: 122–129
   PubMedGoogle Scholar
• Thor H., Moldeus P., Orrenius S. Metabolic activation and hepatotoxicity: effect of cysteine, N-acetylcysteine and methionine on glutathione biosynthesis and bromobenzene toxicity in isolated rat hepatocytes. Archives of Biochemistry and Biophysics 1979; 192: 405–413
   PubMed Web of Science ®Google Scholar
• Zampaglione N., Jollow D. J., Mitchell J. R., Stripp B., Harrick M., Gillette J. R. Role of detoxifying enzymes in bromobenzene-induced liver necrosis. Journal of Pharmacology and Experimental Therapeutics 1973; 187: 218–227
   PubMed Web of Science ®Google Scholar
• Zhuo Z., Casciano D. A., Heflich R. H. Use of the human liver cell line HepG2 in a modified Salmonella reversion assay. Cancer Letters 1986; 32: 327–334
   Google Scholar